** Shares of Zevra Therapeutics ZVRA.O rise 5.14% to $7.77
** Zevra says it enters agreement to sell its rare pediatric disease Priority Review Voucher $(PRV.UK)$ for $150 million
** The U.S. FDA granted the company PRV in September 2024 after approval of its drug Miplyffa
** Miplyffa is indicated for use in combination with co's other genetic disorder drug, miglustat, to treat rare neurological condition passed genetically in adult and pediatric patients 2 years of age and older
** PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA
** ZVRA has fallen 7.19% YTD
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。